Evaluating the changing economic and market scenario and recommending a future growth strategy for a biotech company.

1. `` A CASE STUDY OF BIOCON LTD BUILDING A BIOTECH POWERHOUSE

2. `` EVOLUTION GLOBAL SCENARIO INDIAN SCENARIO GROWTH VECTOR ANALYSYS BIOCON LTD ASIA PACIFIC CHALLENGES SWOT ANALYSIS SWOT SUMMARY ROAD MAP

6. `` GLOBAL SCENARIO

7. `` GLOBAL SCENARIO

19. ``

25. `` SWOT ANALYSIS THREATS RISK IN DRUG DISCOVERY GENERICS MKT B’ING OVERCROWDED STRICT IP REGULATOTY LAWS LOW COST CHINESE COMPETITORS INTENSE COMPETITION IN CRO WEAKNESS STATINS - 80% BIOCON TURNOVER(45% REVENUES) MKT REDN FROM $22-3Bn CAPACITY BUILD UP IN CRO LEAST EXPERTISE IN FINAL STAGE MARKETING OPPORTUNITY $ 82Bn WORTH GLOBAL B’BUSTERS FACING PATENT EXPIRY INDIA SHARE OF GLOBAL GENERICS MKT INC TO 33% FROM 4% ENZYMES MKT GROWING AT 6.5% OUTSOURCING TO REDUCE COST INDIA PREFERRED DESTINATION FOR CLINICAL TRIALS ($70Mn-20% Gr) 177 Mn(G)/ 45Mn(I) DIABETIC PATIENTS 9Mn CANCER CASES VENTURE CAPITALISTS STRENGTH CONSOLIDATED SKILLS IN ENZYMES DERISKED BUSINESS MODEL US FDA CERTIFIED MKT LEADER IN INDIA CORE COMPETENCE IN MOLECULAR BIOLOGY LOW COST CLINICAL RESEARCH DEVELOPMENT OF ORAL INSULIN

26. `` SWOT SUMMARY E X T E R N A L E N V I O R N M E N T INTERNAL FACTORS STRENGTHS WEAKNESS T H R E A T S O P R T N T Y SEARCH BUILDUP CRO CAPACITY TO BE ABLE TO MEET ANTICIPATED DEMAND (UTILISE VENTURE CAPATILISTS) EXPLOIT UTILISE MKT LEADER STATUS/ FDA CERTIFICATION TO INCREASE GLOBAL MARKET SHARE FAST TRACK DEVELOPMENT OF ORAL INSULIN MAINTAIN SKILL LEVEL IN ENZYMES FOR CONSOLIDATION AVOID LOOSING CRO MARKET TO COMPETITORS BY FAST TRACKING CRO CAPABILITY CONFRONT LOW COST COMPETITORS/ RISK BY MAINTAINING BOTH CORE COMPETENCE IN MOLECULAR BIOLOGY AND LOW COST CLINICAL RESEARCH

27. `` GROWTH VECTOR ANALYSIS EXISTING MARKET (USA) EXPANDING MARKET (EUROPE & CANADA) NEW MARKET (CHINA & INDIA) PRESENT PRODUCTS IMPROVED PRODUCTS FUTURE PRODUCTS BIO-FUELS ORAL INSULIN CANCER DRUGS GENERICS (4% - 33%) UPGRADE MANUFACTURING CAPABILITIES INDUSTRIAL ENZYMES CRO ORAL INSULIN CANCER DRUGS STATINS (SHRINKING EXISTING MKT) ENZYMES INDUSTRIAL ENZYMES CRO ORAL INSULIN CANCER DRUGS ENZYMES GENERICS FORM ALLIANCES

28. ``